1. Generics Bulletin

US Patients Increasingly Reliant On Pharmacy Discount Cards For Generics

Discount Card Users Pay Almost Double Out-Of-Pocket Than Those Using Their Insurance Benefit

 
• By Chloe Kent

IQVIA has published a white paper examining the growing reliance on pharmacy discount cards to pay for prescriptions in the US.

Buyer passing cash to pharmacist in US drugstore
A growing number of US patients are paying for their prescriptions with pharmacy discount cards • Source: Shutterstock

A white paper published by IQVIA has found that use of pharmacy discount cards by US patients has grown nearly 60% in the last five years, despite the fact that those using the cards pay on average almost double out-of-pocket than those who use their insurance benefit.

Use of discount cards has risen drastically over the past five years, from 3.3% of pharmacy adjudications in 2017 to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

AAM Celebrates Court Backing Over Minnesota Pricing Law

 
• By Dave Wallace

The AAM has welcomed a US appeals court decision backing an injunction against a Minnesota state law on drug pricing, following an earlier favorable district court ruling.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Governor Newsom Expands Discounted Naloxone Availability To All Californians

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

More from Policy & Regulation